Levodopa (L-Dopa)

Sinemet, Madopar, Sirio e altri

Bibliografia - Quali fonti bibliografiche per Levodopa (L-Dopa)?

1. Antonini A. et al., Mov. Disord., 2007, 22 (8), 1145.


2. Antonini A. et al., Neurodegener. Dis., 2008, 5 (3-4), 244.


3. Barbeau A., Trends Pharmacol., Sci., 1981, 2, 297.


4. Berkowitz D.M., McCallum R.W., Clin. Pharmacol. Ther., 1980, 27 (3), 414.


5. Calne D.B., Reid J.L., Drugs, 1972, 4, 49.


6. Cilia R. et al., Arch. Neurol., 2008, 65 (12), 1604.


7. Corvol J.C. et al, Ann. Neurol., 2011, 69 (1), 111 disponibile online http://onlinelibrary.wiley.com/doi/10.1002/ana.22155/full


8. Domen R.E., J Med., 1998, 65, 89.


9. FDA, Drug Safety Comunication, 2010, 31 marzo, disponibile online www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm206363.htm


10. FDA, Drug Safety Comunication, 2010a, 20 agosto, disponibile online www.fda.gov/Drugs/DrugSafety/ucm223060.htm


11. Hassin-Baer S., Clin. Neuropharmacol., 2006, 29 (6), 305.


12. Homberg J.C., Presse Med., 1999, 28 (13), 703.


13. International Parkinson Disease Genomics Consortium, Lancet, 2011, 377 (9766), 641.


14. Ikebe S. et al., Parkinsonism Relat. Disord., 203, 9 Suppl. 1, S47.


15. Katzenschlager R. et al., Neurology, 2008, 71 (4), 474.


16. Lamberti P. et al., Mov. Disord., 2005, 20 (1), 69.


17. Manca D. et al., Mov. Disord., 2009, 24 (15), 2293.


18. Nagayama H. et al., Parkinsonism Relat. Disord., 2010, 17 (3), 150.


19. Nutt J.G. et al., NEJM, 1984, 310, 483.


20. Nyholm D. et al., Neurology, 2005, 64 (2), 216.


21. Ogawara K. et al., Ann. Neurol., 2000, 48, 624.


22. Ozer F. et al., Neurol. Res., 2006, 28 (8), 853.


23. Parkinnen L. et al., Neurology, 2011, 77 (15), 1420.


24. Parkinson Study Group CALM Cohort Investigtors, Arch. Neurol., 2009, 66 5), 563.


25. Postuma R.B. et al., Neurology, 2006, 66 (12), 1941.


26. Rajfer S.I. et al., NEJM, 1984, 310, 1357.


27. Refsum H. et al., J. Nutr., 2006, 136 (6 Suppl.), 1731S.


28. Roger J.D. et al., Arch. Neurol., 2003, 60 (1), 59.


29. Samanta J., Hauser R., Expert. Opin. Pharmacother., 2007, 8, 657.


30. Shindler J.S. et al., Br. J. Clin. Pharmac., 1984, 18, 959.


31. Solla P. et al., Neuropsychiatr. Dis. Treat., 2010, 6, 483.


32. Stocchi F. et al., Ann. Neurol., 2010, 68 (1), 18.


33. Ward C., J. Neurosci. Nurs., 2005, 37 (3), 160.


34. Wong S., Steiger M., BMJ, 2007, 334 (7598), 810.


35. Zangaglia R. et al., Clin. Neuropharmacol., 2010, 33 (2), 61.


36. Zappia M. et al., Clin. Neuropharmacol., 2002, 25 (2), 79.


37. Zesiewicz T.A. et al., Clin. Neuropharmacol., 2006, 29 (3), 106.


38. Zoccotella S. et al., Mov. Disord., 2009, 24 (7), 1028.